Effect of rosuvastatin on serum cTNI, Cys-C, Hcy and myocardial enzyme, Inflammatory cytokines in acute myocardial infarction with PCI surgery

• Main Authors: Na Shen, Zeng-Xin Yang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-11-01
• Series: Journal of Hainan Medical University
• Subjects: Rosuvastatin; Acute myocardial infarction; Percutaneous coronary intervention surgery; Myocardial enzyme; Inflammatory cytokines
• Online Access: http://www.hnykdxxb.com/PDF/201621/12.pdf

Objective: To observe the effect of rosuvastatin on serum cTNI, Cys-C, Hcy and myocardial enzyme, inflammatory factors in acute myocardial infarction with percutaneous coronary intervention (PCI) surgery. Methods: A total of 80 patients with acute myocardial infarction were randomly divided into control group (40 cases) and experiment group (40 cases), the control group were given atorvastatin on the basis of basic therapy, and the experiment group were given rosuvastatin on the basis of basic therapy. The change of serum cTNI, Cys-C, Hcy, LDH, CK, CK-MB, IL-1β, IL-6, IL-17 in 24 hours and 8 weeks after PCI surgery of two groups were compared. Results: The serum cTNI, Cys-C, Hcy, LDH, CK, CK-MB, IL-1β, IL-6, IL-17 in 8 weeks after PCI surgery of two groups were significantly lower than that of 24 hours after PCI surgery (P<0.05). The serum cTNI, Cys-C, Hcy, LDH, CK, CK-MB, IL-1 β, IL-6, IL-17 in 8 weeks after PCI surgery of experiment group were significantly lower than that of 8 weeks in control group (P<0.05). Conclusions: Rosuvastatin can significantly decrease the myocardial enzyme, inflammatory cytokines in acute myocardial infarction with PCI surgery. It plays an important role in protecting the heart function, reversing myocardial damage, and inhibiting cardiac remodeling.